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Following myomectomy the rate of fertility is restored and pregnancy may be attempted with a good outcome. In the present study
a 3 month treatment with OCs in a group of women after a myomectomy was evaluated. The drug compliance and side eﬀects,
the beneﬁts of OC in order to reduce symptoms, to increase post-surgical hemoglobin levels and to avoid an early pregnancy after
myomectomy were analyzed. A group of women (n = 55) each with myoma ≥5cm was recruited: they presented menorrhagia,
pelvic pain, dyspareunia and dysmenorrhae. After laparotomic myomectomy the women were divided into 3 groups. Group 1:
women (n = 16) treated with pill A (15mcg of ethynilestradiol + 60mcg of gestodene); group 2: women (n = 23) treated with pill
B (20mcg of ethynilestradiol + 100mcg of levonorgestrel); group 3: women (n = 16) treated with a placebo (oral calcium). After
three months from myomectomy and treatment patients in each group reported a reduced menorrhagia, dismenorrhea and pelvic
pain. Serum haemoglobin levels increased in all women (P<. 05). No pregnancy occurred in any group and the compliance was
good. A post surgery treatment by using oral contraceptives guarentees pregnancy prevention, associated with reduction of pain,
and improvement of haematologic conditions.
Copyright © 2009 Stefano Luisi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Uterine leiomyomata is a major source of morbidity among
women of reproductive age [1] .T h e ya r eb e n i g nt u m o r so f
smooth muscle, commonly referred to as ﬁbroids. Despite
the importance of these tumors, little is still known about
their epidemiology or aetiology [2]. Epidemiologic studies
suggest that risk is inversely associated with age at menarche,
parity and age at ﬁrst birth and positively associated with
years since last term birth [3], so the incidence of leiomy-
omata rises through out the reproductive years [2, 4], while
the incidence of surgery is lowest in the menopausal years
[4, 5]. This pattern suggests a dependence on ovarian steroid
hormones, but the role of these agents in the etiology of
uterine leiomyomata remains unclear [6, 7]. Uterine ﬁbroids
cause a variety of symptoms, such as menorrhagia, pelvic
pain, infertility, reproductive dysfunction (like pregnancy
loss and pregnancy complications), but sometimes they
are completely asymptomatic [8]. The eﬀect of estrogen-
progestinoralcontraceptives(OCs)onthevolumeofuterine
leiomyomata is not well characterized.
OCs may play a role in the development or growth of
leiomyomata [9] and a signiﬁcantly elevated risk among
w o m e nw h oﬁ r s tu s e dO C sa ta g e s1 3 – 1 6y e a r sc o m p a r e d
with non-OCs users has been shown [1]. On the other
hand, the little available epidemiologic data have suggested
ap r o t e c t i v ee ﬀect of OCs in the risk of ﬁbroids [10, 11].
Low-dose OC use provides the beneﬁt of a reduction in
the duration of menstrual bleeding, with resultant improve-
ment in haemoglobin levels, without increasing uterine
size [12]. Antiprogesterone which induces ovarian acyclicity
also decreases size of leiomyomata, thus antiprogesterone
may provide a novel mode of management of leiomyomata
[13].
Therefore, the association between oral contraceptive
and the risk of uterine ﬁbroids is still unclear. Uter-
ine leiomyomata is the ﬁfth cause of hospitalization for
gynecologic conditions unrelated to pregnancy in women
aged 15–44 and the primary indications for hysterectomy
among women of all ages [14]. The range of alternatives
to hysterectomy includes medical regimens (levonorgestrel-
releasing intrauterine system), a wide range of endometrial2 International Journal of Endocrinology
Table 1: Distribution of patients according to age, dysmenorrhoea,
menometrorrhagia and pelvic pain at previous surgery.
Variable Patients (n◦)%
Age
30–35 years 9 16
35–40 years 42 77
>40 years 4 7
Presence of symptoms 48 87
Dysmenorrhoea 8 16
Menometrorrhagia 36 75
Pelvic pain 22 45
Absence of symptoms 7 13
ablative techniques, and where ﬁbroids are the primary
pathology myomectomy and uterine artery embolization.
Abdominal myomectomy is an eﬀective surgical alter-
native to hysterectomy one for therapy of symptomatic
uterine ﬁbroids, it preserves fertility and femininity [15].
Myomectomy is associated with a favourable outcome
in infertile women, particularly if no other complication
variable is present [16]. The location of the myomata may
play an important role in determining infertility. Both
large intramural and subserous myoma are thought to
interfere with conception and reduce the eﬀectiveness of
assisted reproduction cycles [17]. The size of the myoma
may represent another important prognostic factor, 5cm
in diameter being the size limit which appears to justify
myomectomy. Restoration of fertility after myomectomy has
been reported, with pregnancy rates ranging between 44 and
52% [18].
The time to postmyomectomy conception is short, with
∼80% of pregnancies occurring during the ﬁrst year follow-
ingsurgery,however,intheﬁrstmonthsafteramyomectomy
a gestation the risk of uterine rupture is higher [17].
In the present study a 3-month treatment with OCs in
a group of women after a myomectomy was evaluated. In
addition, the drug compliance and side eﬀects, the beneﬁts
of OC in order to reduce symptoms, to increase post-
surgical hemoglobin levels and to avoid an early pregnancy
after myomectomy was analyzed. Moreover, we investigated
the risk of uterine leiomyomata in relation to short-term
contraceptive use.
2.MaterialsandMethods
The study was approved by the Institutional Review Board
of the Academic Health Center of Siena, and an informed
consent was obtained from each participant.
A group of 55 women (aged 30–45, BMI 22–25) with
ultrasound and a histologically conﬁrmed diagnosis of
uterine ﬁbroids was recruited from September 2006 to April
2007. All the women presented unexplained infertility and
had only one large intramural or subserosal myoma mea-
suring ≥5cm and underwent on laparotomic myomectomy
(these myomas were not as suitable for the laparoscopic
approach). None of the subjects had taken any medications
Table 2: Distribution of myomas according to location and
diameter.
Myoma Patients %
Diameter (cm)
5 − < 82 2 4 0
8 − < 10 27 49
>10 6 11
Location
Intramural 42 76
Subserous 13 24
for at least 3-months before the study. Most of them
presented a variety of female reproductive problems and
symptoms, such as menorrhagia (excessive uterine bleeding
occurring at regular intervals or prolonged uterine bleeding
lasting more than seven days) [19] or irregular bleeding (n =
36), pelvic pain (n = 22), dyspareunia and dysmenorrhoea
(n = 15).
To investigate the outcome, women were instructed to
keep (i) a diary of menstrual bleeding (number of days of
menstrual ﬂow and total number of pads/tampons used),
rating the blood loss on a visual analog scale from zero (no
blood loss) to 10 (gushing-type bleeding); (ii) the presence
of side eﬀects and overall satisfaction with treatment was
rated on a ﬁve-level scale (very satisﬁed, satisﬁed, uncertain,
dissatisﬁed,andverydissatisﬁed);(iii)aquestionnaireforthe
assessment of pain symptoms (dysmenorrhea, dyspareunia
and pelvic pain) by using a 10 points Visual Analog Scale
(VAS) [20].
The clinical characteristics of the women enrolled in the
study are shown in Table 1, while the characteristics of the
myomas are shown in Table 2.
Exclusion criteria were von Willebrand’s disease or coag-
ulopathies (known or suspected), or a history of hormone-
dependent malignancies; known or a history of deep-vein
thrombosis, active thrombophlebitis, thromboembolic dis-
order, or cerebrovascular accident, myocardial infarction or
ischemic heart disease, untreated hypertension, liver disease,
anyendocrinedisorderotherthancontrolledthyroiddisease,
and a smoking habit of one pack or more of cigarettes per
day.
After laparotomic myomectomy and a normal postop-
eration time (5 days) without post-operative complications,
the women were divided into three randomized groups
according to the treatment:
(i) group 1: treated with pill A (n = 16) (15mcg of
ethynilestradiol + 60mcg of gestodene) (Arianna,
Bayer Schering, Berlin, Germany);
(ii) group 2: treated with pill B (n = 23) (20mcg of
ethynilestradiol + 100mcg of levonorgestrel) (Mira-
nova, Bayer Schering, Berlin, Germany);
(iii) group 3: treated with placebo (n = 16) (oral
calcium).International Journal of Endocrinology 3
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Figure 1: Serum haemoglobin concentration after treatment in the three groups. Group 1: women treated with 15mcg of ethynilestradiol
+ 60mcg of gestodene; group 2: women treated with 20mcg of ethynilestradiol + 100mcg of levonorgestrel; group 3: women treated with a
placebo. ∗ = P<. 05.
We used two diﬀerent pill formulations to compare if
there were any diﬀerences between second (levonorgestrel)
and third (gestodene) generation progestin.
Since it was a blind study to each group was said to
u s eb a r r i e rc o n t r a c e p t i o ni no r d e rt oa v o i dp r e g n a n c y .A l l
the women were controlled in the following 3-months after
surgery.
Before and after 3-months a pelvic transvaginal ultra-
sound (LAB 70 ESAOTE SpA, Genova, Italy) evaluation
was done, and peripheral blood was drawn to measure red
and white blood cell count, hematocrit, hemoglobin, and
platelets.
The serum results are expressed as a mean of ±SE,
and diﬀerences between groups were assessed by using the
unpaired t-test. Probability values of less than .05 were
considered statistically signiﬁcant.
3. Results
After the treatment the three groups of patients showed
reduced menorrhagia, dysmenorrhoea, pelvic pain (P<. 01)
and increased serum haemoglobin concentration (P<. 05)
(Figure 1). The haemoglobin levels showed to be about the
same in the three groups after myomectomy.
During the transvaginal pelvic ultrasound no gyneco-
logical complications were noted in any of the subjects. A
reduction of symptoms occurred in OCs users faster than in
the control group (Figure 2). No pregnancy was reported in
any of the patients.
No relevant side eﬀects (spotting, bloating, acne, mood
swing, weight gain or loss, headaches, breast pain) were
registered in any of the groups after 3-months of treatment.
4. Discussion
The present results showed that a 3-month treatment with
OCs after myomectomy is associated with regular menstrual
cycles, increased serum haemoglobin concentration without
pelvic pain, dysmenorrhoea, and risk of pregnancy.
Myomectomy is frequently performed to preserve or
increasefertility,althoughtheriskoffutureuterineruptureis
a major concern of any surgery to the uterus. For this reason
itisnecessarytoavoidpregnancyintheﬁrstmonthsafterthe
surgery when the risk is higher [21]. Women recruited in our
present study were >30 years and each had a intramural or
subserosal myoma. The rationale of the OC treatment was to
give a contraceptive cover at least in the ﬁrst 3-months after
myomectomy.
In women with menstrual disorders, such as menorrha-
gia, the OC treatment reduces the menstrual blood loss and
increases the serum haemoglobin concentration, reducing
the incidence of anemia. Oral contraceptives represent also4 International Journal of Endocrinology
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Figure 2: Improvement of symptoms (dysmenorrhoea, pelvic pain, menorrhagia) after myomectomy and OCs use.
the main medication used to treat dysmenorrhea. Although
several mechanisms underlying the dysmenorrheal pain
relief attained by OC use have been reported, suppression of
prostaglandin (PG) synthesis, which leads to reduced uterine
contractions, represents one of the most probable pathways
[22].
The eﬀect of OCs on myomas is still not fully clear.
Evidence showed that both reproductive factors and oral
contraceptive use at a young age, inﬂuence the risk of uterine
leiomyomata among premenopausal women [23]. In a case
report, a 45-year-old woman, with a symptomatic uterine
leiomyoma, presented a reduced myoma volume after the
discontinuation of OCs [24].
To the contrary after a 1-year study Friedman et al.
showed that in most women with leiomyomas, low-dose OC
use provides the noncontraceptive beneﬁt of a reduction in
the duration of menstrual ﬂow, with resultant improvement
in hematocrit, without increasing uterine size [25].
The prolonged use of the last generation of oral con-
traceptives does not increase the uterine myoma volume
and furthermore it produces a noteworthy reduction in the
duration of menstrual ﬂow with consequent increase in
hematocrit [26].
We chose a short-term trial since the majority of
women undergoing myomectomy despite of hysterectomy
forﬁbroidswantapregnancyintheimmediatepostoperative
period. We suggested them the use of the pill to improve
symptoms and menstrual bleeding. Moreover, we wanted to
underlined the rapid improvement of the clinical condition
during the ﬁrst 3-months after surgery in association with
oral contraceptive.
Therefore, an oral contraceptive post-surgery treatment
foratleast3-monthsguaranteesthepreventionofpregnancy,
allowing a faster improvement of the clinical and haemato-
logic conditions, without increasing the risk of recurrency.
Condensation. The use of a low-dose of estro-progestins
after myomectomy guarantees the prevention of pregnancy,
allowing a faster improvement of the clinical and haemato-
logic conditions.
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